We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
Cancer tissues showed weak to moderate cytoplasmic staining with additional membranous positivity in several cases. A majority of prostate cancers and occasional cases melanoma, endometrial, cervical, liver, ovarian and breast cancers showed strong staining. Several cases of lymphoma, renal, testicular and skin cancers were negative.
Moderate to strong cytoplasmic and/or membranous immunoreactivity was displayed by most malignant cells. Lymphomas, hepatocellular carcinomas and several testicular cancers were negative.
The protein encoded by this gene is one of two effectors of the small GTPase RAB5A/Rab5, which are involved in a signal transduction pathway. Both effectors contain an N-terminal Bin/Amphiphysin/Rvs (BAR) domain, a central pleckstrin homology (PH) domain, and a C-terminal phosphotyrosine binding (PTB) domain, and they bind the Rab5 through the BAR domain. They are associated with endosomal membranes and can be translocated to the nucleus in response to the EGF stimulus. They interact with the NuRD/MeCP1 complex (nucleosome remodeling and deacetylase /methyl-CpG-binding protein 1 complex) and are required for efficient cell proliferation. A chromosomal aberration t(12;22)(q24.1;q13.3) involving this gene and the PSAP2 gene results in 22q13.3 deletion syndrome, also known as Phelan-McDermid syndrome. [provided by RefSeq, Oct 2011]
